MRD status at post-remission treatment in first CR for favorable cytogenetic risk AML, including RUNX1-RUNX1T1 and CBFB-MYH11, can be used to guide further management [33]. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.